Evelien Van Dijck

Ms. Evelien Van Dijck

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2021 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
SDSara Diels
Sara Diels
Bart CuypersBart Cuypers
Bart Cuypers
ATAsta Tvarijonaviciute
Asta Tvarijonaviciute
BDBruno Derudas
Bruno Derudas
EDEvelien Van Dijck
Evelien Van Dijck
WHWim Van Hul
Wim Van Hul
Background: The multifactorial nature of non-alcoholic fatty liver disease cannot be explained solely by genetic factors. Recent evidence revealed that DNA methylation changes take place at proximal promoters within susceptibility genes. This emphasizes the need for integrating multiple data types to provide a better understanding of the disease’s pathogenesis. One such candidate gene is paraoxonase-1 (PON1). Substantial interindividual differences in PON1 are apparent and could influence disease risk later in life. The aim of this study was therefore to determine the different regulatory aspects of PON1 variability and to examine them in relation to the predisposition to obesity-associated fatty liver disease. Results: A targeted multi-omics approach was applied to investigate the interplay between PON1 genetic variants, promoter methylation, expression profile and enzymatic activity in an adult patient cohort with extensive metabolic and hepatic characterisation including liver biopsy. Alterations in PON1 status were shown to correlate with waist-to-hip ratio and relevant features of liver pathology. Particularly, the regulatory polymorphism rs705379:C > T was strongly associated with more severe liver disease. Multivariable data analysis furthermore indicated a significant association of combined genetic and epigenetic PON1 regulation. This identified relationship postulates a role for DNA methylation as a mediator between PON1 genetics and expression, which is believed to further influence liver disease progression via modifications in PON1 catalytic efficiency. Conclusions: Our findings demonstrate that vertical data-integration of genetic and epigenetic regulatory mechanisms generated a more in-depth understanding of the molecular basis underlying the development of obesity-associated fatty liver disease. We gained novel insights into how NAFLD classification and outcome are orchestrated, which could not have been obtained by exclusively considering genetic variation.

27 September 2022 in Genes
Verified
Journal Article
Open access
PDF file
EDEvelien Van Dijck
Evelien Van Dijck
SBSigri Beckers
Sigri Beckers
SDSara Diels
Sara Diels
THTammy Huybrechts
Tammy Huybrechts
AVAn Verrijken
An Verrijken
WHWim Van Hul
Wim Van Hul
Recently, it was reported that heterozygous PCSK1 variants, causing partial PC1/3 deficiency, result in a significant increased risk for obesity. This effect was almost exclusively generated by the rare p.Y181H (rs145592525, GRCh38.p13 NM_000439.5:c.541T>C) variant, which affects PC1/3 maturation but not enzymatic capacity. As most of the identified individuals with the heterozygous p.Y181H variant were of Belgian origin, we performed a follow-up study in a population of 481 children and adolescents with obesity, and 486 lean individuals. We identified three obese (0.62%) and four lean (0.82%) p.Y181H carriers (p = 0.506) through sanger sequencing and high resulting melting curve analysis, indicating no association with obesity. Haplotype analysis was performed in 13 p.Y181H carriers, 20 non-carriers (10 with obesity and 10 lean), and two p.Y181H families, and showed identical haplotypes for all heterozygous carriers (p < 0.001). Likewise, state-of-the-art literature concerning the role of rare heterozygous PCSK1 variants implies them to be rarely associated with monogenic obesity, as first-degree carrier relatives of patients with PC1/3 deficiency are mostly not reported to be obese. Furthermore, recent meta-analyses have only indicated a robust association for scarce disruptive heterozygous PCSK1 variants with obesity, while clinical significance is less or sometimes lacking for most nonsynonymous variants.

4 August 2025 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
EDEvelien Van Dijck
Evelien Van Dijck
SLSteven Van Laere
Steven Van Laere
ELEmilie Logie
Emilie Logie
STSteven Timmermans
Steven Timmermans
EFErik Fransen
Erik Fransen
WBWim Vanden Berghe
Wim Vanden Berghe
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, but its pathophysiological mechanisms remain elusive. It is a progressive disease, encompassing hepatic steatosis, steatohepatitis with (out) fibrosis, and ultimately cirrhosis and hepatocellular carcinoma. DNA methylation (DNAm) is dysregulated in MASLD and may play a central role in its pathogenesis. Additionally, aging is associated with MASLD and shares common processes of chronic inflammation and oxidative stress. Therefore, this study focuses on DNAm changes in relation to MASLD progression and epigenetic age acceleration (EAA). Liver biopsies from 22 individuals with varying MASLD status were analyzed using Infinium MethylationEPIC BeadChip arrays. Strikingly, progression of MASLD was characterized by gradual DNAm changes, revealing multiple associated KEGG pathways. Additionally, Horvath’s EAA significantly correlated with MASLD stage and individual histological MASLD parameters while LiverClock’s EAA correlated only with MASLD stage. In contrast, both Horvath’s intrinsic EAA and HepClock’s EAA showed no significant correlations. Integrative analyses, leveraging both gradual MASLD and Horvath’s EAA DNAm signatures, gene expression (n = 118), and a MASLD-specific transcriptional regulatory network, identified (regulon-specific) transcription factors implicated in MASLD and EAA progression, representing a transcription factor-network of redox (ferroptosis), immune, and metabolic/endocrine related epigenetic processes. Gradual DNAm changes were found to align with progression of MASLD and EAA, with EAA a potential nonbiased quantitative biomarker for MASLD. Integrative analysis highlighted potential new therapeutic transcription factor targets, with special emphasis on AEBP1 and emerging nuclear receptors including CAR(NR1I3), MR(NR3C2), GR(NR3C1), and ESRRG, underscoring the potential of epigenetic redox-metabolic therapies for MASLD.

29 August 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
EDEvelien Van Dijck
Evelien Van Dijck
SDSara Diels
Sara Diels
EEErik Erik
Erik Erik
TCTycho Canter Cremers
Tycho Canter Cremers
AVAn Verrijken
An Verrijken
WHWim Van Hul
Wim Van Hul
The paraoxonase (PON) gene family (including PON1, PON2, and PON3), is known for its anti-oxidative and anti-inflammatory properties, protecting against metabolic diseases such as obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). In this study, the influence of common and rare PON variants on both conditions was investigated. A total of 507 healthy weight individuals and 744 patients with obesity including 433 with histological liver assessment, were sequenced with single-molecule molecular inversion probes (smMIPs), allowing the identification of genetic contributions to obesity and MASLD-related liver features. Polymorphisms rs705379 and rs854552 in the PON1 gene displayed significant association with MASLD stage and fibrosis, respectively. Additionally, rare PON1 variants were strongly associated with obesity. This study thereby reinforces the genetic foundation of PON1 in obesity and various MASLD-related liver features, by extending previous findings from common variants to include rare variants. Additionally, rare and very rare variants in PON2 were discovered to be associated with MASLD-related hepatic fibrosis. Notably, we are the first to report an association between naturally occurring rare PON2 variants and MASLD-related liver fibrosis. Considering the critical role of liver fibrosis in MASLD outcome, PON2 emerges as a possible candidate for future research endeavors including exploration of biomarker potential.

26 May 2025
Verified
Thesis
Closed access
EDEvelien Van Dijck
Evelien Van Dijck
Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) are complex diseases with multifactorial etiologies. Their prevalence is continuously rising and poses a huge burden on human health and health-care systems. Although recent breakthroughs for therapeutic targets have been established in both diseases, the pathophysiological disease mechanisms remain elusive, limiting the development of precise and effective biomarkers, prognostic tools and treatment strategies. To address these issues, this thesis presents targeted genetic and untargeted epigenetic analyses aimed at elucidating the mechanisms and key players involved. Chapters 3 and 4 of this thesis focus on rare variants, which have a presence of less than 1% in the general population, but might significantly contribute to disease heritability on a population scale. In Chapter 3, we examined the association between the rare p.Y181H proprotein convertase subtilisin/kexin type 1 (PCSK1) variant and obesity in a case-control setup. We found no difference in carrier frequency between the two cohorts, indicating that in our cohort, the variant did not contribute to obesity susceptibility. Chapter 4 investigates a family of anti-inflammatory and anti-oxidative genes with high expression in the liver. This paraoxonase (PON) gene family comprises three members: PON1, PON2 and PON3. Using targeted sequencing, we identified a PON1 SNP that was associated with MASLD-associated fibrosis. Additionally, rare variants in PON1 and PON2 were associated with obesity and MASLD-related fibrosis, respectively. Although genetic research refines our understanding of the genetic architecture of obesity and MASLD, genetics alone can't explain the rapidly rising obesity and MASLD rates. Important factors such as environment and lifestyle contribute to disease development and progression and influence gene expression through epigenetic mechanisms like DNA methylation (DNAm). As such, Chapter 5 constitutes the second part of this thesis, where epigenetic marks, specifically DNAm, were explored in MASLD patients using an untargeted approach. We identified that changes in liver DNAm occur in a gradual fashion during MASLD progression. Additionally, epigenetic age acceleration (EAA), a measure of biological aging, showed significant correlation with MASLD progression, indicating biomarker potential. Further integrated downstream analysis combining DNAm, gene expression data and network analysis for both MASLD and EAA measures identified numerous transcription factors (TFs) related to metabolism, immune function and redox homeostasis. As a result, our study highlights the potential of these TFs to be used as biomarkers and/or therapeutic targets in the future.